AI in Precision Medicine Market Set for Explosive Growth to USD 32,410 Million by 2033, Led by North America's 42% Market Share | DataM Intelligence

The Global AI in Precision Medicine Market reached USD 1,703.19 Million in 2024 and is expected to reach USD 32,410 Million by 2033, growing at a CAGR of 38.7% during the forecast period of 2025 to 2033.

This substantial growth is driven by the increasing demand for personalized treatments, advancements in AI technologies like deep learning and natural language processing, and the rising prevalence of chronic and genetic diseases. Key factors include the integration of AI-powered precision diagnostics and therapeutics that enable more accurate disease diagnosis, treatment selection, and drug discovery.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- http://datamintelligence.com/download-sample/ai-in-precision-medicine-market?ram

United States: Key Industry Developments
✅ November 2025: North America solidified its leadership in the AI in precision medicine market through strategic collaborations among established companies like Abbott Laboratories, enhancing innovation and access to advanced healthcare solutions.​

✅ October 2025: Leading firms including IBM, Microsoft, Google, and NVIDIA advanced AI applications by analyzing vast patient datasets in cancer research, identifying genetic anomalies to enable highly specialized precision medications.​

✅ August 2025: AI technologies expanded with machine learning for diagnostics, drug discovery, and genomic data integration, supporting personalized treatment plans and predictive modeling for chronic diseases.​

Europe: Key Industry Developments
✅ November 2025: The NHS AI Lab and AI in Health and Care Award in England progressed real-world evaluations of AI technologies in care pathways, boosting deployment in precision medicine.​

✅ July 2025: The European Commission's 1+ Million Genomes initiative improved secure data access and standards across Member States, promoting interoperability for AI-driven precision medicine growth.​

✅ July 2025: AI integration in precision medicine advanced genomic analysis, predictive analytics, and pharmacogenomics to tailor treatments based on individual genetic profiles.

Key Merges and Acquisitions(2025):
✅ Tempus AI acquires Highline Technologies: In November 2025, Tempus AI, a leader in AI-enabled precision medicine, acquired Highline Technologies. This acquisition is specifically aimed at enhancing Tempus's capabilities in data delivery and clinical trial matching, crucial aspects of precision medicine.

✅ Moderna/Merck report positive Phase 3 results for personalized cancer vaccine: In October 2025, Moderna and Merck announced promising Phase 3 results for their personalized mRNA-based cancer vaccine (mRNA-4157/V940). This validates the use of AI in developing highly specific, individualized treatments, which is a core tenet of precision medicine.

✅ Blackwire Labs launches industry-specific advisory solutions: In October 2025, Blackwire Labs launched advisory solutions for the healthcare and government sectors. The increasing integration of cybersecurity in health tech protects sensitive patient data essential for AI-driven precision medicine platforms.

Market Segmentation Analysis:
-By Technology: Deep Learning Leads with 36.2% Market Share
Deep learning dominates the AI in precision medicine market technology segment with approximately 36.2% market share as of 2024. It excels by processing vast data volumes and recognizing complex patterns in genomics, patient records, and other healthcare data, accelerating diagnostic procedures and personalized treatment development. Other technology segments include machine learning, querying methods, context-aware processing, and natural language processing.

-By Component: Software and Hardware vs Services
The market is segmented into hardware, software, and services. Software and hardware together make up the majority market share, with services forming a smaller but essential part, supporting AI integration, maintenance, and support functions. Software solutions, in particular, drive market growth by enabling complex data analysis and personalized medicine capabilities.

-By Application: Oncology Tops with Highest Market Share
Applications are primarily in oncology, neurology, cardiology, respiratory, and others. Oncology leads with the highest market share due to AI's crucial role in cancer detection, diagnosis, genetic mutation analysis, and personalized treatment planning, significantly improving clinical outcomes. Diagnostics and screening show rapid growth driven by AI's ability to efficiently analyze complex medical images and genomic data.

Purchase this report before year-end and unlock an exclusive 30% discount: https://www.datamintelligence.com/buy-now-page?report=ai-in-precision-medicine-market?ram (Purchase 2 or more Reports and get 50% Discount)

Growth Drivers:
-Advances in AI technology, including machine learning and deep learning, enhance the ability to analyze complex datasets such as genomic, proteomic, and clinical data, leading to more accurate disease risk prediction, diagnosis, and treatment outcomes.

-Growing demand for personalized medicine driven by the need for tailored treatments based on individual genetic makeup and health data.

-Expansion of genomic and multi-omics data, which AI leverages to identify biomarkers and support targeted therapies.

-Increasing investment and collaborations between pharmaceutical, biotechnology, and technology companies to accelerate AI-driven innovation in drug discovery, development, and diagnostics.

-Rising prevalence of chronic and genetic diseases necessitating early disease -detection, cost-effective treatment options, and precision healthcare solutions.

-Support from government initiatives and regulatory frameworks promoting precision medicine research, digital health, and AI adoption in healthcare.

Regional Insights:
-North America commands the largest market share in the AI in Precision Medicine Market at 42.56% as of 2024, driven by substantial NIH grants, FDA clearances for AI devices, and a high concentration of biotech hubs like those supporting Mayo Clinic's AI-integrated oncology practices. Proximity to cloud computing giants and semiconductor suppliers further bolsters supply-chain resilience and rapid clinical validation. This leadership position stems from advanced healthcare infrastructure and heavy R&D investments by firms like IBM and NVIDIA.​

-Europe follows as the second-largest region, benefiting from robust pharmaceutical innovation and regulatory support for AI adoption in precision therapies across countries like Germany and the UK. Collaborative research networks and increasing integration of AI in genomics and personalized treatments fuel its growth, though specific share figures trail North America's dominance.​

-Asia Pacific ranks third, propelled by expanding healthcare investments, rising biotech capabilities, and government initiatives in nations like China and India to advance AI-driven diagnostics and drug discovery. Rapid urbanization and a growing focus on personalized medicine are accelerating market penetration, positioning the region for faster future expansion despite a currently smaller share.

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/ai-in-precision-medicine-market?ram

Key Players:
IBM Corporation | Microsoft Corporation | AstraZeneca | Sanofi | GE Healthcare | Intel Corporation | NVIDIA Corporation | Alphabet Inc. | BioXcel Therapeutics Inc. | Enlitic Inc. | Google Inc. | Illumina Inc.

Key Highlights (Top 5 Key Players) for AI in Precision Medicine Market:
-NVIDIA Corporation leads with deep learning technologies dominating 33.76% market share in AI precision medicine applications, powering genomic pattern analysis and disease prediction models.​

-Microsoft Corporation drives AI adoption through cloud-based platforms integrated across healthcare, supporting precision medicine workflows for major biopharma clients.​

-IBM Corporation advances hybrid AI solutions for drug discovery and patient stratification, leveraging Watson Health tools in oncology precision medicine pipelines.​

-Alphabet Inc. (Google Inc.) excels in AI-driven genomic data processing, with models trained on massive datasets like UK Biobank for pre-diagnostic disease forecasting.​

-AstraZeneca plc accelerates precision medicine via AI models like MILTON, analyzing 500,000 genomes to predict over 1,000 diseases and optimize oncology treatments.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription?ram

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.